Previous 10 | Next 10 |
A newly detected coronavirus variant in Africa created panic and sparked a market selloff in the holiday-shortened week. However, the developers of COVID-19 vaccines and therapeutics advanced while several common stock offerings pressured decliners. Despite the outperformance of biotech stock...
The discovery of a new COVID-19 variant sparked a massive sell-off on Wall Street Friday, with the major averages each plunging more than 2%. However, some parts of the market benefitted from growing concern about a new wave of the virus. For example, stay-at-home stocks received renewed inte...
Gainers: iSpecimen (NASDAQ:ISPC) +71%, Allied Healthcare Products (NASDAQ:AHPI) +68%, Adagio Therapeutics (NASDAQ:ADGI) +34%, Biofrontera (NASDAQ:BFRI) +31%, Moderna (NASDAQ:MRNA) +22%. Losers: Longeveron (NASDAQ:LGVN) -18%, IM Canna...
Established COVID-19 vaccine makers have come under pressure after Pfizer (NYSE:PFE) and a United Nations-backed public health organization announced a licensing pact to allow generic-drugmakers to produce cheaper versions of the company’s experimental COVID-19 pill. Moderna (NASD...
Adagio Therapeutics (NASDAQ:ADGI): Q3 GAAP EPS of -$0.98 misses by $0.23. Cash, cash equivalents and marketable securities of $666.3M Press Release For further details see: Adagio Therapeutics EPS misses by $0.23
FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second Quarter 2022 Enrollment Progressing in ADG20 STAMP Trial for Tr...
WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced par...
The emerging dominance of COVID-19 pills and concerning outlook for vaccine makers dominated healthcare headlines this week amid a flurry of earnings reports. Yet, with an over twofold rise in value, a clinical-stage Alzheimer’s drug developer outshone them all. However, pressure on va...
The promising Phase 3 data disclosed by Pfizer (PFE +10.0%) for its experimental COVID-19 pill have pressured the early-stage developers of rival therapies. Atea Pharmaceuticals (AVIR -9.6%) and Roche (OTCQX:RHHBY -1.8%), its partner in the development of an oral COVID-19 drug called AT-527, ...
Gainers: Chinook KDNY +29%. 4D pharma plc (NASDAQ:LBPS) +28%. ReWalk Robotics RWLK +27%. Grid Dynamics GDYN +26%. BigCommerce BIGC +23%. Endo International plc ENDP +23%. Alzamend Neuro ALZN +22%. Canada Goose GOOS +20%. Assertio ASRT +20%. Losers: Deci...
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in ...
Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses Invivyd’s new data is...
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Heal...